RSV Burden in Children Under 5 Increased in 2021 and 2022 Versus 2015-2019
By Elana Gotkine HealthDay Reporter
FRIDAY, April 19, 2024 -- For children younger than 5 years, the incidence of respiratory syncytial virus (RSV) hospitalization increased in 2021 and 2022 compared with 2015 to 2019, according to a study published online April 18 in JAMA Network Open.
Robert J. Suss, M.P.H., and Eric A.F. Simões, M.B.B.S., M.D., from the University of Colorado School of Medicine in Aurora, conducted a retrospective cohort study involving children younger than 5 years diagnosed with RSV and bronchiolitis at 50 U.S. children's hospitals.
Overall, 37.7 percent of the 924,061 study participants were diagnosed with RSV; 54.0 percent of these participants were hospitalized. The researchers found that for all ages, the incidence rate ratios of hospitalization increased in 2021 and 2022 versus 2015 to 2019. The likelihood of being hospitalized in 2022 compared with 2015 to 2019 was 4.86 times higher for children aged 24 to 59 months and 1.77 times higher for infants aged 0 to 5 months. Regardless of year, Medicaid patients were more likely to be hospitalized than non-Medicaid patients.
"The current findings suggest that the relative risk of RSV-specific health care resource utilization across age groups increased in postpandemic seasons (2021 to 2022) relative to before the pandemic (2015 to 2019)," the authors write. "Furthermore, the risk of hospitalization, as well as emergency department and observation unit admissions, increased in magnitude with age, suggesting a disproportionately increased burden in older children."
One author disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.